SG11202002696VA - Pde9 inhibitor and use thereof - Google Patents
Pde9 inhibitor and use thereofInfo
- Publication number
- SG11202002696VA SG11202002696VA SG11202002696VA SG11202002696VA SG11202002696VA SG 11202002696V A SG11202002696V A SG 11202002696VA SG 11202002696V A SG11202002696V A SG 11202002696VA SG 11202002696V A SG11202002696V A SG 11202002696VA SG 11202002696V A SG11202002696V A SG 11202002696VA
- Authority
- SG
- Singapore
- Prior art keywords
- pde9 inhibitor
- pde9
- inhibitor
- Prior art date
Links
- 229940076380 PDE9 inhibitor Drugs 0.000 title 1
- RVEJWGYZBXCGGM-DNVCBOLYSA-N chembl2179094 Chemical compound C([C@H]([C@@H](C1)C=2NC(=O)C=3C=NN(C=3N=2)C2CCOCC2)C)N1CC1=CC=CC=C1 RVEJWGYZBXCGGM-DNVCBOLYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710900197 | 2017-09-28 | ||
CN201810203538 | 2018-03-13 | ||
CN201810871998 | 2018-08-02 | ||
PCT/CN2018/107461 WO2019062733A1 (en) | 2017-09-28 | 2018-09-26 | Pde9 inhibitor and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002696VA true SG11202002696VA (en) | 2020-04-29 |
Family
ID=65900584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002696VA SG11202002696VA (en) | 2017-09-28 | 2018-09-26 | Pde9 inhibitor and use thereof |
Country Status (12)
Country | Link |
---|---|
US (2) | US10889591B2 (en) |
EP (1) | EP3689876A4 (en) |
JP (1) | JP7347825B2 (en) |
KR (1) | KR102650565B1 (en) |
CN (2) | CN113956252A (en) |
AU (1) | AU2018340475B2 (en) |
BR (1) | BR112020005934A2 (en) |
CA (1) | CA3077134A1 (en) |
SG (1) | SG11202002696VA (en) |
TW (1) | TWI677499B (en) |
WO (1) | WO2019062733A1 (en) |
ZA (1) | ZA202002172B (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3689876A4 (en) * | 2017-09-28 | 2021-05-05 | Nanjing Transthera Biosciences Co. Ltd. | Pde9 inhibitor and use thereof |
CN111410659B (en) * | 2019-01-08 | 2023-08-15 | 药捷安康(南京)科技股份有限公司 | PDE9 inhibitors and uses thereof |
CN111471059B (en) * | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | PDE9 inhibitors and uses thereof |
JP7404616B2 (en) * | 2019-03-08 | 2023-12-26 | トランステラ サイエンシーズ (ナンジン), インコーポレイテッド | Use of phosphodiesterase inhibitors |
TWI830884B (en) * | 2019-03-15 | 2024-02-01 | 大陸商南京藥捷安康生物科技有限公司 | Crystal forms of phosphodiesterase inhibitors, their preparation methods and their uses |
AR119821A1 (en) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | SUBSTITUTED PYRIDOPYRIMIDINOL COMPOUNDS USEFUL AS T-CELL ACTIVATORS |
JOP20220131A1 (en) | 2019-11-28 | 2023-01-30 | Bayer Ag | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
CA3163107A1 (en) * | 2019-11-28 | 2021-06-03 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
AR120823A1 (en) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T-CELL ACTIVATORS |
CN112390750B (en) * | 2020-11-11 | 2022-03-01 | 常州大学 | Quinolinone compounds as selective phosphodiesterase 2 inhibitors and preparation method thereof |
CA3215731A1 (en) | 2021-04-01 | 2022-10-06 | Transthera Sciences (Nanjing), Inc. | Method for preparing phosphodiesterase inhibitor |
TW202332677A (en) | 2021-10-28 | 2023-08-16 | 香港商英科智能有限公司 | Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
KR970705562A (en) * | 1994-08-29 | 1997-10-09 | 오노다 마사요시 | Novel naphthyridine derivatives and medicinal composition thereof. |
JP3373838B2 (en) * | 1999-10-25 | 2003-02-04 | 山之内製薬株式会社 | Naphthyridine derivative |
AR029185A1 (en) | 1999-10-25 | 2003-06-18 | Yamanouchi Pharma Co Ltd | NAFTIRIDINE DERIVATIVE |
US20070203236A1 (en) * | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
WO2009124119A2 (en) * | 2008-04-01 | 2009-10-08 | The Trustes of Columbia University in the City of New York | Phosphodiesterase inhibitors and uses thereof |
EP3354640A3 (en) * | 2011-04-13 | 2018-10-31 | Innovimmune Biotherapeutics, Inc. | Mif inhibitors and their uses |
US10370337B2 (en) * | 2015-07-29 | 2019-08-06 | Merck, Sharp & Dohme Corp. | Oxy-cyanoquinolinone PDE9 inhibitors |
US10376504B2 (en) * | 2015-07-29 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Substituted quinolinones as PDE9 inhibitors |
WO2017019724A1 (en) * | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Phenyl-cyanoquinolinone pde9 inhibitors |
EP3689876A4 (en) | 2017-09-28 | 2021-05-05 | Nanjing Transthera Biosciences Co. Ltd. | Pde9 inhibitor and use thereof |
-
2018
- 2018-09-26 EP EP18860570.3A patent/EP3689876A4/en active Pending
- 2018-09-26 AU AU2018340475A patent/AU2018340475B2/en active Active
- 2018-09-26 JP JP2020517946A patent/JP7347825B2/en active Active
- 2018-09-26 CN CN202111451207.7A patent/CN113956252A/en active Pending
- 2018-09-26 CN CN201811121994.7A patent/CN109575016B/en active Active
- 2018-09-26 SG SG11202002696VA patent/SG11202002696VA/en unknown
- 2018-09-26 WO PCT/CN2018/107461 patent/WO2019062733A1/en unknown
- 2018-09-26 CA CA3077134A patent/CA3077134A1/en active Pending
- 2018-09-26 KR KR1020207011727A patent/KR102650565B1/en active IP Right Grant
- 2018-09-26 BR BR112020005934-0A patent/BR112020005934A2/en unknown
- 2018-09-27 TW TW107134059A patent/TWI677499B/en active
-
2019
- 2019-12-04 US US16/702,711 patent/US10889591B2/en active Active
-
2020
- 2020-05-04 ZA ZA2020/02172A patent/ZA202002172B/en unknown
-
2021
- 2021-01-05 US US17/141,385 patent/US11434248B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20200115384A1 (en) | 2020-04-16 |
EP3689876A4 (en) | 2021-05-05 |
KR20200065013A (en) | 2020-06-08 |
CN109575016B (en) | 2022-01-04 |
EP3689876A1 (en) | 2020-08-05 |
AU2018340475B2 (en) | 2023-01-19 |
JP2020535194A (en) | 2020-12-03 |
US11434248B2 (en) | 2022-09-06 |
RU2020112895A3 (en) | 2021-11-02 |
AU2018340475A1 (en) | 2020-04-23 |
RU2020112895A (en) | 2021-10-28 |
BR112020005934A2 (en) | 2020-10-06 |
KR102650565B1 (en) | 2024-03-26 |
ZA202002172B (en) | 2023-04-26 |
JP7347825B2 (en) | 2023-09-20 |
CN113956252A (en) | 2022-01-21 |
CA3077134A1 (en) | 2019-04-04 |
TWI677499B (en) | 2019-11-21 |
US10889591B2 (en) | 2021-01-12 |
WO2019062733A1 (en) | 2019-04-04 |
US20210130366A1 (en) | 2021-05-06 |
TW201915001A (en) | 2019-04-16 |
CN109575016A (en) | 2019-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202002172B (en) | Pde9 inhibitor and use thereof | |
IL272557A (en) | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors | |
IL271025A (en) | Multibiotic agents and methods of using the same | |
IL270330B (en) | Beta-lactamase inhibitors and uses thereof | |
GB201605126D0 (en) | Inhibitors and their uses | |
EP3572400C0 (en) | Ezh2 inhibitor and use thereof | |
IL264813B (en) | 2-oxo-imidazopyridines and their use | |
PT3621694T (en) | Lrrc33 inhibitors and use thereof | |
HUE059778T2 (en) | Urat1 inhibitor and use thereof | |
IL272649A (en) | Ahr inhibitors and uses thereof | |
IL282350A (en) | Rgmc-selective inhibitors and use thereof | |
GB201805021D0 (en) | Method and use | |
GB201805103D0 (en) | Method and use | |
GB201805042D0 (en) | Method and use | |
GB201805024D0 (en) | Method and use | |
IL277749A (en) | Pladienolide compounds and their use | |
IL279276A (en) | Erk inhibitor and use thereof | |
IL270681B1 (en) | Lighting devices and methods for use | |
IL265531A (en) | N 3 -cyclically substituted thienouraciles and use thereof | |
IL269836B (en) | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | |
HK1255029A1 (en) | Gelatinase inhibitors and use thereof | |
HK1231519A1 (en) | Kit and use thereof | |
IL269843B (en) | Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof | |
IL274964A (en) | Anti-chymase aptamer and use for same | |
GB201712049D0 (en) | Novel compounds and their use |